Aster DM Healthcare has earmarked around Rs 4,000 crore to add 4,080 hospital beds across India over the next few years, sharpening its expansion push after shareholders cleared its merger with Quality Care India Ltd (QCIL). The combined platform is now positioning itself for rapid capacity growth in key southern markets, even as it awaits final regulatory and National Company Law Tribunal approvals for the transaction.
Founder and Chairman Dr Azad Moopen said the merged entity will treat India as a key growth market, with a planned scale-up to more than 14,710 beds over the coming years, including the 4,080-plus beds now in the pipeline. Of these, 2,368 beds will be added by Aster DM, with the balance coming from QCIL facilities.
A significant share of the new capacity is concentrated in Bengaluru, where Aster plans two new hospitals: a 430-bed facility on Sarjapur Road and a 500-bed hospital in Yeshwanthpur. The company will also bolster existing infrastructure in the city, with a 350-bed capacity addition at Aster CMI Hospital and 159 new beds at Aster Whitefield.
In Kerala, Aster is building on recent and ongoing greenfield investments. The 263-bed Aster Kasaragod Hospital became operational in October 2025, widening access in the northern part of the state. Work is underway on the 454-bed Aster Capital Hospital in Thiruvananthapuram, alongside a 100-bed expansion at Aster Medcity in Kochi, one of the group’s flagship tertiary care centres.
Beyond Karnataka and Kerala, the network is adding specialised capacity in Andhra Pradesh and Telangana. Planned projects include a 300-bed Women and Children’s Hospital in Hyderabad and a 75-bed expansion at Aster Ramesh, Ongole. The emphasis on women’s and paediatric services indicates a push into high-demand specialty segments, particularly in fast-growing urban catchments.
Dr Moopen framed the shareholder approval for the merger as an endorsement of the group’s long-term strategy and the value-creation potential of the enlarged network. “The strong support from our shareholders reflects their confidence in the strategic rationale of this merger and the long-term value it will deliver,” he said, noting that the combined platform is being built to serve “millions of patients across the country.” He added that by bringing together Aster DM Healthcare and QCIL, the group is creating a “scaled, future-ready healthcare platform with the clinical depth, operational strength and governance framework required” for its growth ambitions.
The transaction also cements Blackstone’s role as a key institutional partner in the India-focused business. Aster’s promoters and Blackstone will hold equal board representation and exercise joint control over the merged entity, while independent directors will make up 50 per cent of the board. According to Moopen, the partnership “combines Aster’s legacy of patient-centric care and physician leadership with the institutional strength and growth expertise of Blackstone,” signaling an alignment between clinical priorities and scale-driven expansion.
Leadership continuity and integration are central to the post-merger blueprint. Moopen will continue as Executive Chairman of the combined company, while Varun Khanna, currently Group Managing Director at QCIL, is set to take over as Managing Director and Group CEO. The structure is expected to support operational integration across the expanded hospital portfolio while maintaining physician-led oversight at the top.
With over 4,000 new beds planned and a clear capital commitment in place, Aster DM Healthcare’s next phase of growth is likely to reshape its presence in India’s private hospital landscape, particularly in the south. Pending completion of regulatory processes, the merged platform will be closely watched as a test case for how promoter-led hospital chains and global private equity can jointly scale capacity in a market marked by rising demand, regional disparities in access, and increasing expectations on quality and governance.
